What are you looking for today?

Naing, Aung, Meric-Bernstam, Funda, Stephen, Bettzy, Karp, Daniel D, Hajjar, Joud, Rodon Ahnert, Jordi, Piha-Paul, Sarina A, Colen, Rivka R, Jimenez, Camilo, Raghav, Kanwal P, Ferrarotto, Renata, Tu, Shi-Ming, Campbell, Matthew, Wang, Linghua, Sabir, Sarjeel H, Tapia, Coya, Bernatchez, Chantale, Frumovitz, Michael, Tannir, Nizar, Ravi, Vinod, Khan, Saria, Painter, Jeane M, Abonofal, Abulrahman, Gong, Jing, Alshawa, Anas, McQuinn, Lacey M, Xu, Mingxuan, Ahmed, Sara, Subbiah, Vivek, Hong, David S, Pant, Shubham, Yap, Timothy A, Tsimberidou, Apostolia M, Dumbrava, Ecaterina E Ileana, Janku, Filip, Fu, Siqing, Simon, Richard M, Hess, Kenneth R, Varadhachary, Gauri R and Amir Habra, Mouhammed (2020) Phase 2 study of pembrolizumab in patients with advanced rare cancers. Journal for ImmunoTherapy of Cancer, 8 (1). e000347. ISSN 2051-1426

Document

Abstract

Abstract

Background Patients with advanced rare cancers have poor prognosis and few treatment options. As immunotherapy is effective across multiple cancer types, we aimed to assess pembrolizumab (programmed cell death 1 (PD-1) inhibitor) in patients with advanced rare cancers.

Methods In this open-label, phase 2 trial, patients with advanced rare cancers whose tumors had progressed on standard therapies, if available, within the previous 6 months were enrolled in nine tumor-specific cohorts and a 10th cohort for other rare histologies. Pembrolizumab 200 mg was administered intravenously every 21 days. The primary endpoint was non-progression rate (NPR) at 27 weeks; secondary endpoints were safety and tolerability, objective response rate (ORR), and clinical benefit rate (CBR).

Results A total of 127 patients treated between August 15, 2016 and July 27, 2018 were included in this analysis. At the time of data cut-off, the NPR at 27 weeks was 28% (95% CI, 19% to 37%). A confirmed objective response (OR) was seen in 15 of 110 (14%) evaluable patients (complete response in one and partial response in 14). CBR, defined as the percentage of patients with an OR or stable disease ≥4 months, was 38% (n=42). Treatment was ongoing in 11 of 15 patients with OR at last follow-up. In the cohort with squamous cell carcinoma (SCC) of the skin, the NPR at 27 weeks was 36%, ORR 31%, and CBR 38%. In patients with adrenocortical carcinoma (ACC), NPR at 27 weeks was 31%, ORR 15%, and CBR 54%. In the patients with carcinoma of unknown primary (CUP), NPR at 27 weeks was 33%, ORR 23%, and CBR 54%. In the paraganglioma–pheochromocytoma cohort, NPR at 27 weeks was 43%, ORR 0%, and CBR 75%. Treatment-related adverse events (TRAEs) occurred in 66 of 127 (52%) patients, and 12 (9%) had grade ≥3 TRAEs. The most common TRAEs were fatigue (n=25) and rash (n=17). There were six deaths, all of which were unrelated to the study drug.

Conclusions The favorable toxicity profile and antitumor activity seen in patients with SCC of skin, ACC, CUP, and paraganglioma–pheochromocytoma supports further evaluation of pembrolizumab in this patient population.

Trial registration number NCT02721732

Item Type: Article
Depositing User: Matthew Campbell
URI: https://sure.sunderland.ac.uk/id/eprint/13129

Further Details

More Information

Depositing User

Identifiers

Item ID
13129
Identification Number
ISSN
2051-1426

Users with ORCIDS

ORCID for Matthew Campbell

Catalogue record

Date Deposited
05 Feb 2021 10:41
Last Modified
04 Jun 2025 17:23

Contributors

Author
Aung Naing
Author
Funda Meric-Bernstam
Author
Bettzy Stephen
Author
Daniel D Karp
Author
Joud Hajjar
Author
Jordi Rodon Ahnert
Author
Sarina A Piha-Paul
Author
Rivka R Colen
Author
Camilo Jimenez
Author
Kanwal P Raghav
Author
Renata Ferrarotto
Author
Shi-Ming Tu
Author
Linghua Wang
Author
Sarjeel H Sabir
Author
Coya Tapia
Author
Chantale Bernatchez
Author
Michael Frumovitz
Author
Nizar Tannir
Author
Vinod Ravi
Author
Saria Khan
Author
Jeane M Painter
Author
Abulrahman Abonofal
Author
Jing Gong
Author
Anas Alshawa
Author
Lacey M McQuinn
Author
Mingxuan Xu
Author
Sara Ahmed
Author
Vivek Subbiah
Author
David S Hong
Author
Shubham Pant
Author
Timothy A Yap
Author
Apostolia M Tsimberidou
Author
Ecaterina E Ileana Dumbrava
Author
Filip Janku
Author
Siqing Fu
Author
Richard M Simon
Author
Kenneth R Hess
Author
Gauri R Varadhachary
Author
Mouhammed Amir Habra

University Divisions

Subjects

Actions (login required)

View Item (Repository Staff Only)

Downloads per month over past year